John Edward Ilett
Plus aucun poste en cours
Profil
John Edward Ilett held several legal positions in various pharmaceutical and biotech companies, including Director-Legal Services at Cephalon, Senior Director & Head-Legal at BioMarin Pharmaceutical, and Secretary & Group General Counsel at Consort Medical Ltd.
He also served as Non-Executive Director at Oxular Ltd.
and Lead Counsel-Europe at Synageva BioPharma Corp.
Additionally, he was Secretary, Chief of Staff & Chief Legal Officer at Orchard Therapeutics Plc.
Prior to his legal career, he graduated from City of London College.
Anciens postes connus de John Edward Ilett
| Sociétés | Poste | Fin |
|---|---|---|
Oxular Ltd.
 Oxular Ltd. BiotechnologyHealth Technology Oxular Ltd. engages in research and experimental development on biotechnology. The firm develops retinal treatments to access specific small spaces in the eye and to provide drug distribution to tissues involved in retinal diseases. The company was founded by Tom Cavanagh and Ronald K. Yamamoto in 2014 and is headquartered in Oxford, the United Kingdom. | Director/Board Member | 28/02/2018 |
| CONSORT MEDICAL PLC | General Counsel | 02/01/2018 |
LGC Group Holdings Ltd.
 LGC Group Holdings Ltd. Miscellaneous Commercial ServicesCommercial Services LGC Group Holdings, Ltd. provides pharmaceutical research and laboratory services. It offers chemical analysis and diagnostic services for the public and private sectors. The company was founded in 1996 and is headquartered in Teddington, the United Kingdom. | General Counsel | 16/02/2015 |
| ORCHARD THERAPEUTICS PLC | Human Resources Officer | - |
| SYNAGEVA BIOPHARMA CORP | Corporate Officer/Principal | - |
Formation de John Edward Ilett
| City of London College | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| Entreprise privées | 9 |
|---|---|
Cephalon, Inc.
 Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Health Technology |
Ligand UK Ltd.
 Ligand UK Ltd. Pharmaceuticals: MajorHealth Technology Ligand UK Ltd. is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market, Moxatag, a once-a-day formulation of the antibiotic and amoxicillin, and frovatriptan, used for the acute treatment of migraine. It also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh and Andre L. Lamotte in 1986 and is headquartered in Winnersh, the United Kingdom. | Health Technology |
Consort Medical Ltd.
 Consort Medical Ltd. Pharmaceuticals: MajorHealth Technology Consort Medical Ltd. is a holding company, which engages in pharmaceutical industry related activities. It focuses on the design, development, manufacture, and sale of medical drug and delivery devices. The company was founded on March 22, 1946 and is headquartered in Kings Lynn, the United Kingdom. | Health Technology |
Oxford GlycoSciences Plc
 Oxford GlycoSciences Plc Pharmaceuticals: MajorHealth Technology Oxford Glycosciences Plc provides biopharmaceutical products. The company develops and manufactures novel products for the diagnosis and treatment of human disease. Its products include bayer, pioneer hi-breddupont, medarex, genmab, glaxosmithkline, neogenesis and pfizer. It was founded in 1988. The company is headquartered in Abingdon, UK. | Health Technology |
LGC Group Holdings Ltd.
LGC Group Holdings Ltd. Miscellaneous Commercial ServicesCommercial Services LGC Group Holdings, Ltd. provides pharmaceutical research and laboratory services. It offers chemical analysis and diagnostic services for the public and private sectors. The company was founded in 1996 and is headquartered in Teddington, the United Kingdom. | Commercial Services |
LGC Ltd.
 LGC Ltd. Miscellaneous Commercial ServicesCommercial Services LGC Ltd. engages in the provision of scientific tool and solutions. It offers genomic analysis tools, drug development solutions, national laboratory, and health research program management. The company was founded in 1842 and is headquartered in Middlesex, the United Kingdom. | Commercial Services |
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
Oxular Ltd.
Oxular Ltd. BiotechnologyHealth Technology Oxular Ltd. engages in research and experimental development on biotechnology. The firm develops retinal treatments to access specific small spaces in the eye and to provide drug distribution to tissues involved in retinal diseases. The company was founded by Tom Cavanagh and Ronald K. Yamamoto in 2014 and is headquartered in Oxford, the United Kingdom. | Health Technology |
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
